$13.38
-1.49-10.02%
Last update: Nov 2, 2:45 PM
ArriVent BioPharma Inc (AVBP) Stock Price, Quote, News & History
AVBPNASDAQ
ArriVent BioPharma announced its Phase 3 lung cancer trial for firmonertinib missed the primary endpoint but showed secondary benefits.
You can purchase shares of ArriVent BioPharma (NASDAQ:AVBP) through any online brokerage.
Other companies in ArriVent BioPharma’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
ArriVent BioPharma has a consensus price target of $32.71.
The stock price for ArriVent BioPharma (NASDAQ: AVBP) is $13.38 last updated November 2, 2026 at 2:45 PM EST.
There are no upcoming dividends for ArriVent BioPharma.
ArriVent BioPharma does not have any upcoming earnings scheduled.
There is no upcoming split for ArriVent BioPharma.
ArriVent BioPharma is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. The company focuses on...
